Praveen D Chatani1, John G Aversa1, James D McDonald1, Tahsin M Khan1, Xavier M Keutgen2, Naris Nilubol3. 1. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Department of Surgery, Division of General Surgery and Surgical Oncology, Endocrine Surgery Research Program, University of Chicago Medicine, Chicago, IL. 3. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: niluboln@mail.nih.gov.
Abstract
BACKGROUND: Small bowel neuroendocrine tumors (SB-NET) frequently metastasize to regional lymphatic or distant sites. Although most prognostication of SB-NET focuses on lymph node involvement, findings from studies of neuroendocrine tumors from other primary sites have suggested that preoperative serum chromogranin-A (CgA) levels may provide a more accurate metric. METHODS: Using the National Cancer Database (2004-2016), we analyzed patients with locoregional SB-NET who underwent curative resection including an adequate lymphadenectomy (n = 1,274). A statistically optimized cut-point was used to dichotomize CgA cohort based on preoperative serum CgA levels. RESULTS: We determined that a CgA ≥139 ng/mL identified patients with significantly shorter estimated mean overall survival (6.6 years vs 7.6 years, log-rank P = .00001). These patients were also older (63 vs 57 years, P < .001) and had higher rates of poorly differentiated tumors (2.1% vs 0.7%, P = .04) or primary tumors >1 cm (88.2% vs 79.2%, P = .001). Clinical features associated with shorter overall survival included preoperative CgA ≥139 ng/mL (HR = 2.19, 95% CI 1.22-3.92; P = .009), age at diagnosis (HR = 1.06, 95% CI 1.03-1.09; P < .001), Charlson-Deyo score ≥2 (HR = 3.93, 95% CI 1.71-9.01; P = .001), and poorly differentiated tumors (HR = 11.22, 95% CI 4.16-30.24; P < .001). Neither lymph node metastasis nor T-stage were independently associated with shorter overall survival in patients with locoregional SB-NET. CONCLUSION: Elevated preoperative serum CgA is an adverse prognostic marker associated with shorter overall survival in patients with locoregional SB-NET. Published by Elsevier Inc.
BACKGROUND: Small bowel neuroendocrine tumors (SB-NET) frequently metastasize to regional lymphatic or distant sites. Although most prognostication of SB-NET focuses on lymph node involvement, findings from studies of neuroendocrine tumors from other primary sites have suggested that preoperative serum chromogranin-A (CgA) levels may provide a more accurate metric. METHODS: Using the National Cancer Database (2004-2016), we analyzed patients with locoregional SB-NET who underwent curative resection including an adequate lymphadenectomy (n = 1,274). A statistically optimized cut-point was used to dichotomize CgA cohort based on preoperative serum CgA levels. RESULTS: We determined that a CgA ≥139 ng/mL identified patients with significantly shorter estimated mean overall survival (6.6 years vs 7.6 years, log-rank P = .00001). These patients were also older (63 vs 57 years, P < .001) and had higher rates of poorly differentiated tumors (2.1% vs 0.7%, P = .04) or primary tumors >1 cm (88.2% vs 79.2%, P = .001). Clinical features associated with shorter overall survival included preoperative CgA ≥139 ng/mL (HR = 2.19, 95% CI 1.22-3.92; P = .009), age at diagnosis (HR = 1.06, 95% CI 1.03-1.09; P < .001), Charlson-Deyo score ≥2 (HR = 3.93, 95% CI 1.71-9.01; P = .001), and poorly differentiated tumors (HR = 11.22, 95% CI 4.16-30.24; P < .001). Neither lymph node metastasis nor T-stage were independently associated with shorter overall survival in patients with locoregional SB-NET. CONCLUSION: Elevated preoperative serum CgA is an adverse prognostic marker associated with shorter overall survival in patients with locoregional SB-NET. Published by Elsevier Inc.
Authors: Benjamin M Motz; Patrick D Lorimer; Danielle Boselli; Joshua S Hill; Jonathan C Salo Journal: J Gastrointest Surg Date: 2017-08-17 Impact factor: 3.452
Authors: Irvin M Modlin; Bjorn I Gustafsson; Marianne Pavel; Bernhard Svejda; Benjamin Lawrence; Mark Kidd Journal: Neuroendocrinology Date: 2010-08-23 Impact factor: 4.914
Authors: James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Manisha H Shah; Whitney S Goldner; Thorvardur R Halfdanarson; Emily Bergsland; Jordan D Berlin; Daniel Halperin; Jennifer Chan; Matthew H Kulke; Al B Benson; Lawrence S Blaszkowsky; Jennifer Eads; Paul F Engstrom; Paul Fanta; Thomas Giordano; Jin He; Martin J Heslin; Gregory P Kalemkerian; Fouad Kandeel; Sajid A Khan; Wajih Zaheer Kidwai; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Craig A Sussman; Nikolaos A Trikalinos; Nataliya A Uboha; Jonathan Whisenant; Terence Wong; James C Yao; Jennifer L Burns; Ndiya Ogba; Griselda Zuccarino-Catania Journal: J Natl Compr Canc Netw Date: 2018-06 Impact factor: 11.908
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Paweł Gut; Agata Czarnywojtek; Jakub Fischbach; Maciej Bączyk; Katarzyna Ziemnicka; Elżbieta Wrotkowska; Maria Gryczyńska; Marek Ruchała Journal: Arch Med Sci Date: 2016-02-02 Impact factor: 3.318
Authors: Aaron Lewis; Mustafa Raoof; Philip H G Ituarte; John Williams; Laleh Melstrom; Daneng Li; Byrne Lee; Gagandeep Singh Journal: Ann Surg Date: 2019-12 Impact factor: 12.969